Response to Stavropoulos
- PMID: 27098365
- PMCID: PMC8031734
- DOI: 10.1111/jch.12831
Response to Stavropoulos
Comment on
-
Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.J Clin Hypertens (Greenwich). 2016 Jan;18(1):43-52. doi: 10.1111/jch.12747. Epub 2015 Dec 10. J Clin Hypertens (Greenwich). 2016. PMID: 26663712 Free PMC article. Clinical Trial.
-
Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?J Clin Hypertens (Greenwich). 2016 Oct;18(10):1073. doi: 10.1111/jch.12832. Epub 2016 Apr 21. J Clin Hypertens (Greenwich). 2016. PMID: 27098448 Free PMC article. No abstract available.
References
-
- Gavin JR III, Davies MJ, Davies M, et al. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31:1693–1702. - PubMed
-
- Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:1087–1095. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
